UJ^^)

vial

vial

a^nii wuivini

aiinu©,©oo

elo.ooo

bo.ooo

1/^ati

^TUTU

^ (e-bidding) riainai^ua^^al^imTibs;ni^<nf;nfit^ iil

b,(i:os;,o^:<i:.<o invi (vm^TUMiua'u^wu^i^iiw'unvi^^'U^i^'i^)

®. bevacizumab s>oo mg/s: mL^ninu®bo

concentrate for solution for

infusion, < mL vial

dr.

on.

©.

(^. telmisartan do mg tablet, ©

tablet (^©.^^.^^.i?;^ -bo^^si^s:)

<t. tiotropium ©d meg inhalation

powder, hard capsule, © capsule

m. perindopril arginine mg

film-coated tablet, © tablet

te. Diphtheria-Tetanus-acellular

Pertussis, Hepatitis-B

(Recombinant), Inactivated Polio

and Haemophilus Influenzae

type b Vaccine {^l^.^iei.eiGi.ei^^

(e-bidding)<

is)s>e-GP i^w-iiiriTUvi

njjfiTmjs ^.fl.6U 1UV\

.nkp-hospital.go.th Vila

www.gprocurement.go.th viiae(a'U0nuvn-3lviif^v?viun8L0^J o-^cn^icij-ciiteoo w'a

v. m ..$^.:.?lu.:$9

l.tJ.^. nivru^

lann^aun^ (Electronic Government Procurement: e - GP) ^)8-3n<5JJ'u^j?nsn-3 wiuvi

lJ.tJ.'O. finviu^i

silo.^^

ltl.iJ.'a. nnviu^

Government Procurement: e - GP)

(Electronic<5^n^ai^^0^^<ao.

mi.

j ru ^u

ni.

/ of (U 1/to.

n^a-a

3ja( ly

vial

vial

©,©oo

b!o,ooo

^TUTUbo,ooo

i<u©.©

(^. telmisartan do mg tablet, ©

tablet ((^©.GvG^.G^^!.G^G^ -too<^©G^s;)

c^. tiotropium @^ meg inhalation

powder, hard capsule, © capsule

cn. perindopril arginine <SL mg film-

coated tablet, © tablet

to. Diphtheria-Tetanus-acellular

Pertussis, Hepatitis-B

(Recombinant), Inactivated Polio

and Haemophilus Influenzae type

b Vaccine (c®.G^^!.G^^!.G^^!

©. bevacizumab sioo mg/s: mL

concentrate for solution for

infusion, < mL vial ((e>.G^^LG^^!.G^^

^cnaltlmitj rm

^^TUVI ©to n3J/nWU5

^a

(e-bidding)

o.©te

wi3Jvipiiun^i3Jfn<5^ (Electronic Government Procurement: e -

(Electronic Government Procurement: e - GP)

0.©o

b.to

O.dt:

b.©

b.to

to.

(to) ij^jman?m?b'uvi o

(to)

©.to

tftyman^^diyvi to

<si.<s:

wyv

(b)

PDF File (Portable Document Format)

y

©

©

PDF File (Portable Document

©

©.to (©

©

^^

Format)

^(®) Vi^a (to)

(on)

yei^y (aifi) a

(anS) uas

wi^ly^

(to)

(n)

Cinei ^au.afuil'u to ehy pia

01.© gbuv! © aa'

en.

\J.\J.^J. nivru^

Iutuvii

(and) mmjluLana^^ia

^ninJfEy^^iana^aTuvi b ^iijjuuulu'tia ®.b(b)

niviu^

w3u'tiata'ua^s^^a^a-3^hadi-3'ua^t^fa^viiaua ^nu^u

tu

1\J

s^.cn w8<u<iiai,a'ua^s^(ria-3Lauaniviu^i,iaia-9ija<u<^(a(^jldmu cnbct: tu uun

tu

tu<lJ^•^l^Lta^

v^^ni^ann'aa'u

d

uasvniainFnpiavithEJ

i?CUQ"anpntu^iJu."UTJ PDF File (Portable Document Format)

a/ ^a^68a

or.

b tu isvi^n-anan o^.oo "u. ^ sib.oo ^. cu

(find)

PDF File (Portable Document Format)h

is

b pitu^tu ^n

®.b

PDF File (Portable Document

e'ay ayaa

m\i

%/a/

Format)

^ enmuji/liHia ®.b

dr.

^ www.gprocurement.^o.th

wiutu

(and)(b)

s:.©o

. (b)

wnu^ia

i^a^idnnin^^vina<uit)'unni3^'!y^i'^ni'5U^<{i''uaa'i-3Li)tJ5'3i3J

(Upload)

.cno m.

PDF File naiu^a^a<ufi''un'mei'ua'nf!n

PDF File (Portable Document

u.nu^nvum b^bs> i^

naui^ua-sipn wa<u^at?i'ua5n'5^^a^j'5i-3^fqjqji^^ ^

w

u a-a ^b.eno uStr^u bctrbsi

wd

mi

vtiafhtiiyvra'l^^6]

vh^ L^

e8aL'uaTUTu

(en)

sfnmy

(b)

uu ituu^i wa^ai?fuaiia L^iei'ua

en

c^.cn

mm

iNe!^'^^a

^

^^a

mi.

(win^))

.s^ (to)®

(en)

®.s^ (to)nnvru^

1/wiaria'UTUiMmn'u m Tuvi

(fe) w

u^K^^^a-3^i^vi^niUii8iTU^fy^yiiiliu^nu^ui,luivinmj^aofis <ztu

®.sn

^nu^ia b.®rnalu (^ Tuvfimi

^.on

^malu (^ Tuviim"5

b.

nu

naau

vnn

w^'U^ia

<\*a

(anil)

(©) Vila do)(en)

iiatvia

(te)

main gti tu

wu

©o.

© tl

Ji d.n; *^1/td1/ a/

®>.m vnia

mEJiilwi^fta Hn^l'uaV^iaaa^ o.bo

l

- Not less than 4.0 ml/vial

- 235-315 mOsm/kg

- wi^^ > 10 |Llm Imn^ 6,000 a^fii^/container

- TO3SF1 > 25 |Hm ^iinu 600 aunifi/container

^^^nawTU^iuvtasijTu finished product specification

- o^awTu

- 5.9 - 6.3

- 22.5-27.5 mg/ml

- 0.8 - 1.2 x 10* U/mg

- ^^n^wTU^iJJvtast/l'u finished product specification

9. Extractable volume

8. Osmolality

7. Particulate matter

6. Bacterial endotoxins

5. Sterility test

4. pH

3. Content of Protein

2. Potency

1. Identification

Finished product

fmmm

Bevacizumab 100 mg imJiu'^^ 4 ml

S^^ vial ^a^

l.

2.

3.

4.

Bevacizumab 100 mg/4 ml Injection

ection

(inaa-^a ^na^ii

miajj^ j

nrsum^lanaus)

X^(inti

a-a^a..

a-a-aa„..../.<sp(y..,n-nurm(ui^ai^tw/ity^usini^ra)

a^itia..,...„.^...̂ ,.,fiTsarm

4.1

4.

(Raw material)

(Certification of analysis) tuEJT5<uvi?i<3i,il<u

Certificate of pharmaceutical

3.2

3.1

3.

product

(GMP Vila GMP/PICs)

2.2

2.1

2.

l.l.l Tunirijviul^LnYiw^wlvrib'^ivifl'lviEJ tojiejIk^ vi^j. 2 vila ej.2

1.1.2l^n^dlvkiliiLiihmmamiuikiJ^^^j vhjiej^-3 viej. 3 ^ia ej.2

1.1.31'un^iSvii^luEJTunm^nnpii^'iJisiviPi miiEJfva viej. 4 vtia ei.2

1.2 Tuph^ja^ruYi^iiJEmEn viej. 1 vila L.l sua-3EJivii,?i'ua'n^nv^fa3J^'iEj^

(finished product specification) n^aiviaEJiuvm-^

anfii^viiacfii^n/ii^diLni^aunl^iJiJivifaiJ finished

product specification

- a u.

^^^^ 'iJtutaj'iin)

jnfi w^aii j

' ..!.^.'[fl.f?.r^umiu.asw'ii^aia'inufn^

^a^aaa^^tu

f^*^

ti^^ia^^tia^^n

(vn-aamili"

(iraa-n^^a

(inaan^

(inaa^

(un-jam

aaI(unai

a^u)tl^"511.

^ 1QJ1^*\ ^At ^ ^^^1 1 ^1 ft/ ^ ^Uo^lrU7i l/llfl<^ J 1

H^^iaia^Tumi

wti^aLaDTunT^

nrsurrr!

(ina^-aw^na Ta

n^^jjrng

n j

•u lanaug)

'^qntnmi'nnSj

ian)

haunf)^^^

j

" niiainj

na'umnj^^

a wiijiiT^y /v

wrnmn

laa^^a

fr^^wn/ii

i

ii'i'̂ am'

(^n-jam

inau-ja

(ira

(un

I(una

(u

(iraa

a^a

a^a

aia

2 rai,i>fh: ibsnau^hEnfl^^u Haemophitus Influenzae type b

1 dose (0.5 ml) ib^na-u^ha^ntn

-toxoid ^nfU^fafia^jUienrm 30 IU

-toxoid ^in^atn^^vi^tih'bJonrm 40 IU

-antigen ^im^alan'a'U'i^^n^^nHuifjvis 3 tj-u^^ [toxoid ^nni^alani'u (PT) 25

filamentous haemagglutinin (FHA) 25 Mpi^nfu u^s pertactin (PRN; 69 kiloDalton outer

membrane protein) 8 Mflinfu]

-surface antigen (HBsAg) ^a^famjaniau^ (HBV) ^aniHvfuifjvis 10 Mfl^nfu-^alofeil'U^la'^fjnvinHvijj^qviB 3 ui^^ (^^^^ 1 ^naV^us Mahoney: 40 D-antigen units, v\im 2

cnowus MEF-l: 8 D-antigen units, WJflvi 3 fntiwuq Saukett: 32 D-antigen units)

-polyribosyl-ribitol-phosphate capsular polysaccharide (PRP) ^a-^i^a Haemophiltus

influenzae type b (Hib) 10 lulflinfu vmn^^nWuiaviBi.n'isaEJfnj tetanus toxoid 20-40

- ehuvi l

l vuba'urs^iYflj'ri thsnauffnEj 2 ^Tu^Ci

vimziln lanTu tifamjani^uii Itl^la S^

Diphtheria-Tetanus-acellular Pertussis, Hepatitis-B (Recombinant), Inactivated Polio

and Haemophilus Influenzae type b Vaccine

l.

ombinant), inactivated Polio and

b Vaccine

Diphtheria-Tetanus-acellular Pertu

Haemophit

^ t Si.fi.

WTJ^awTU^njJvi'aK'ut'U finished product specification

Between 1.1 and 1.7 mg/ml

Not more than 0.2 mg/ml

- Less than 25.00 EU/ml

- Not less than 0.5 ml

- ^n^wTU

- 5.8-6.8

- ^^iiaw'i^nsjvb^'iiki finished product specification

Pi^awTU^nuvi'a^'utu finished product specification

- ^aamwniJvtasnjTu finished product specification

- ^^^wTUsniivi'j^'ul'u finished product specification

- ^^i^awn-u^najvb^ijTu finished product specification

Between 17 and 34 mcg/ml

- ^^aw'i'uonijvta^ijl'u finished product specification

w'a^aw'TUwnsjms'ui'u finished product specification

- ^maw'i'u^najvta^'uTu finished product specification

^na&h'u^'iuvhi^'ijl'u finished product specification

9. Residual pertussis toxin activity

8. Aluminium content

7. Formaldehyde content

6. Bacterial endotoxins

5. Volume in container

4. Sterility test

3. pH

2. Potency

Tetanus toxoid

Diphtheria toxoid

Pertussis

- PT antigen

- FHA antigen

- PRN antigen

Hepatitis B antigen

Polio- Polio Virus Type 1

- Polio Virus Type 2

- Polio Virus Type 3

1. Identification test

Finished product

1. anviTU DTPa-HBV-IPV vaccine

fhinhsnauphEnaiflVu

Tuviw^^ Tuauano^iatn4.

- a n.fi.

Certificate of pharmaceutical product

(GMP vila

2.1

2.2

2.

finished product specification

(finished product specification)

(via. 2, via.3, via.4 vila a.2 uehu^n^oi)

vonao-3 via. 2 vila a.2

vunasva via. 3 vila a.2

viinafva via. 4 vila a.2

via. l vila a.ii

l.l.l

l.l.2

1.1.3

l.l

1.

- Not more than 20.0%

- Between 0.12 and 0.18 m/vial

- Less than 5.0 lU/dose

- Not more than 3.0%

- FinaWTU

- 5.0-7.0

- Not less than 80% of amount of PRP stated on

the label

S^nawiwiuvta^ijTu finished product specification

8. Free polysaccharide

7. Aluminium content

6. Bacterial endotoxins

5. Water content

4. Sterility test

3. pH

2. Content

1. Identification test

2. ^nviTU Hib vaccine

U.f). ^bs

'n 2 tl as7.

Long Term Stability7.lt"unii{uwviiiiauaninjjnnrn'i 2 il a^

6.

7.

5.4

vi5.1 Ti'uaDaia<t)a-3aT^ei-3jja<u^a-3i,viaal3J'uaani'i l il 6

5.2

i i5.

7 tu

4.1 wi?ma^n^^^a^?^^^na?h^njnari'i'3'uaEJ 1v

^^4.

(Certification of analysis

(Raw material)

3.1

3.2

3.

- ti U, Ute

wa

- wr^^w'iupnjjviis'u'lu finished product specification

- ^nawnu^niiviis'iji'U finished product specification

- 95.0-105.0% of the labeled amount of Perindopril

arginine

- ^^aw'i^'mvb^'ut'u finished product specification

4. Disintegration time

3. Uniformity of dosage units

2. tJiin^ui^^fn^imy

1. identification

Finished product

tu

^aaai

ib^nau^ha^nan Perindopril arginine 5 mg

1.

2.

3.

4.

ablet

Perindopril arginine 5 m Tablet

Perin

5.

5.

5.

7 tu

4.2

%>cj O€\CU II^JG til U - 1/1/^titn wmvimvru^^ t<uvn<^afjoifijj<u^vnT,iJ^n<iu

4.1 wia<uan^n^ia-3?i-3^naEJi^3a4JJiaJi-3'uaa 1

4.

(Certification of analysis)

(Raw material)3.2

3.1

3.

product

Certificate of pharmaceutical

(GMP vile GMP/PlCs) Tuvun^anvi

2.2

2.1

2.

specification

•(finished product specification) niomatb^vm-3

finished product

via. l vile a.l1.2

{Sm^u^oitinjJeif/a^rt./) n^jn^^aKW'iiiaiain'um?

n^ ^nai?)

un^O-aaiivif)

j^*^^^^aiiav('3^j

nisvi-aa aii?a-an?)(^*W

n??^m?

(iraainJ?i

(u^an^^a

(in-asuf

(inaana

(inaai

(mail

(in-aan.

ti?K51U

lS/UflSi'51

A

A

A

a^^a

A

A

Taatu)

a-a^a

biuia^Tum?

Biaiainum?

??uni?

5?nm?

n??um?

-^triffv^wina

n^ium^

mini^

i^ajj^ j

umoiau lanausj

5ii Daaan)

^|/^^ n

. flon^mnnoi) ^

K—^^\ a-ttia

un-aaa^a n

umi^aa ^

(iraanna

(in-^an

(mair

(m^a

(mach

(

(a-aiia

a-^a

A

a-5?a

a-wia.

A

as7.2lun^cuwvisjiCouoniiTuaon^n 2 il ^^

7.31'un^aimjjl<oan^i'<uuutjaa^iw^m^?in<tfn^^eiu^ja (Bioequivalence)

a/7.1 l^n^dH'uvi^uj&j'LiEnjninfifrin 2 t) ^^a<iSaim'iiij1i^KiwanT3Pin'bn Long Term Stability

6.

7.

mviw

ria^5.4

5.3

(in^rnhn^H^oilnmn)

(vnarfn^ ufhuii^^unf)

^^?.^.ir. .̂t^'J..fvminTiuasia^nufm(^ii-JBuaiu ^jja^^)"^Jvftvi U^'tl̂ n/J^3 ^.

(U1EJi)13/ ?(19DflH1tU}^T.^^.01^1101^

(Uia^^^a^?)

(in-aamajj^s'i^^tm^aii)

\J^s5Tun^iiim^

a^^iE

"hS tjijioi)

aa

/% m w

^uaswihEiiainur

^aswihtiLaTniJf

. n^irn^

n^a3fvn

(vnavMW

^nnvtuag^

rn'iiirn

nTOim

vi riqn^THUT

Unauvi'sj .' \S

(tnau-aaa tn^^)

(•un-ja-JSmitm^

(uiaaflTBB

A~Aplf

a-j^a

<ai

a^a

1.1 luaipi'^yfni^i'uvisiiia'u^nfuao (via. 2, via.3, via.4 vila a.2

l.l.l fcsaivii^l'ua'iviwapil'uiJi^ivif'ilvia vtuna^-3 via. 2 vila a.2

•1.1.2 n^^u'^ivl'uaTuimtviarniLi.'iJ^^i^ vnnaa^3 via. 3 vtia a.2

1.1.3 fvstu'^i.vltiaTunmann^i^'Ll'^s^i.viPi viina^^ via. 4 Vila a.2

- wnaWTU^nuvtas'u'l'U finished product specification

- ^^^iawii^iJvtasn/l'U finished product specification

- 90.0-110.0 % of the labeled amount of Telmisartan

- ^yjaeh'uisnajytes'iji'U finished product specification

4. Uniformity of dosage units

3. Dissolution test

2. tl^^jiai^naiaifi'nj

1. Identification

Finished product

fmuu/a-a

tuwpi

Telmisartan 80 mg

l.

2.

3.

4.

Telmisartan 80 mg Tablet

5.

4.

(Certification of analysis)

(Raw material)

^iatha^flj^a^wa

3.2

3.1

3.

Certificate of pharmaceutical

(GMP viia GMP/PlCs) luvun^tnvi2.1

2.2 n^dlviiiliJBniIim^nn(?h<i<ibsi,vifl

^nuviafii

product

2.

specification

(finished product specification)

^aiJ finished product

n

via. l viia jj.is/

1.2

a-niaQj^/^-!,-^(nna^un)

Long Term Stability

7.3 l'un^^'^1ljj1'iiiai^i''uau\ja^wa-3^warn^^n<yn^^efU3j^ (Bioequivalence)

7.2

6.

7. ^an^man *]

7.1 ^uni^uwwsJUJEJ'UEnaninnfnn 2 tl

n'au

ii 2 tl a^

5.4

.Qt^.(unau-aaa

(m-isiianij.^>,lanaiis)

- ^^r^Wi'u^yvtaisij'i'U finished product specification

^^^iawTUfiniiYtasi'utt! finished product specification

^^^iawnwiuvb^'ul'U finished product specification

- ^^iawTU^^iuvta^'ijTu finished product specification

95.0-105.0% of the labeled amount of Tiotropium

- ^lam^^nuvb^'u'l'u finished product specification

6. Uniformity of dosage units

5. Particulate contamination

4. Fine particle dose

3. Uniformity of delivered dose

2. \Ji3J1tU^ii81^1pifll

1. Identification

Finished product

1.itltiw^ai^t^iaTm^tJ^^aK^^iai^^al^^aKn^^ia-a HandiHaler inhalation^vv

2.l^ 1 UfinJH?i'ibvfla'U^nEi^iai Tiotropium bromide monohydrate vkvitnjivhfvu Tiotropium

18 meg ua^St^a-3 HandiHaler

3.

4.

Tua^aia

nhalation

Tiotropium 18 meg Capsule for Inhalation

Tiotropiu

- d u.

and

14 1V(in-aamnaumty^u

^CC

and

ant

andl^r.^C....C(

awe..

(vnaana uma-ana

7 tu

4.2

4.1

Hwa^i^i^^^

(Raw material)

(Certification of analysis) luan^^vi^itlii

product

Certificate of pharmaceutical

(GMP Vila GMP/PlCs) luvm^^anvi2.1

2.2

3. sl

3.1

3.2

4.

2.

1.1.1n^divikili^iviw^lmb^ivipilviEj vunaf^ via. 2

1.1.2nirilvii^^uaiih^hmafn'aU'u-Jtma ranacva via. 3

1.1.3n^rijvhil'uaiihm^in^i'^'ibsmf1! viinafva via. 4

1.2 Icifl'njamjvi^i.ila'uai via. 1 iia^a^viiema^nf^^aiJina^

(finished product specification)

aswa^uumanfmnni^iauntaiiniNiajj finished product

specification

7.3 ^'unidimjjl'Bai^^m'U'u^iK^a^Ciw^m^Pin^niTJiauiviatJvn^api^^n (comparative clinical

trial)

Long Term Stability7.11'un^tu^i'uviti!a'uanjjnjjifimli 2 il

^iaa^w^-^ano'ua-^ai^'uvi^i'ua'uH

a/7.2l^n^nHtjmtfjEJ'UEnij'i'uayfm 2 tl ^^

6.

7.

] riau5.4

1 tl 3 w^u5.1

5.2

5.3

5.

Y\ a^Gn/loct^^o ^^TU^ to ^f^Pl^ VI.Pi. ted^bo

uiauv^viEji,^aT!najil

^n.

81-30-3

a. inywuswpi

i a/ o

g:.1o

si.

c^ao.oo DTVl/Box

loo.acTl invi/Tab

g^gtIgtI "UIVl/Tab

a.^aGn.s^GTl UiVl/Vial

a^.ac^o.oo UiVlA/ial

•snpn^iavi'ii^a

(in vi)

a Box

^o Tab/Box

cno Tab/Box

a Vial

a Vial

iiunpi-uiia

Tiotropium 18 meg Capsule for

Inhalation (sCa)

Telmisartan 80 mg Tablet ^^.a)

Perindopril arginine 5 mg Tablet (sCa)

Diphtheria-Tetanus-acellular

Pertussis, Hepatitis-B (Recombinant),

Inactivated Polio and Haemophilus

Influenzae type b Vaccine {sl.b)

Bevacizumab 100 m/4 ml Injection

(s^.to)

rmfmtn

SI

en

a

vi

en. Tuvinivrupinpnn^n-3

: \d,siog:,oSis:.s:o

si n^rma. ^iaTpii-ami: